Federal grants to Nostopharma LLC
Nostopharma LLC in Potomac, Maryland received $2.0 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Technology, Innovation, and Partnerships, with $1.0 million. In fiscal 2025 it was awarded $423,792.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$2.0 million
- Awards4
- Awarded in FY 2025$423,792
- Largest award$1.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $256,000 |
| FY 2023 | 1 | $318,796 |
| FY 2024 | 2 | $1.0 million |
| FY 2025 | 2 | $423,792 |
Programs that fund Nostopharma LLC
| Program | Awards | Amount |
|---|---|---|
| Technology, Innovation, and Partnerships | 1 | $1.0 million |
| National Center for Advancing Translational Sciences | 2 | $770,982 |
| Engineering | 1 | $256,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| National Science Foundation | 2 | $1.3 million |
| Department of Health and Human Services | 2 | $770,982 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Sbir phase II: improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries -the broader impact/commercial potential of this small business innovation research (SBIR) phase II project is the development of the safe and efficacious treatment for orthopedic and t | Technology, Innovation, and Partnerships | August 15, 2024 | $1.0 million |
| Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva - fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disease that affects around 1 in 1.5–2.0 million live births, i | National Center for Advancing Translational Sciences | July 3, 2025 | $407,792 |
| Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease - there is a critical need to improve drug development strategies for rare diseases, as more than 7000 rare and neglected diseases currently have no treatments available. At the sa | National Center for Advancing Translational Sciences | August 10, 2023 | $363,190 |
| Sttr phase i: improved drug delivery platforms for localized and sustained drug deposition for traumatic injuries -the broader impact/commercial potential of this small business technology transfer (STTR) phase i project seeks to reduce complications due to trauma. Current traumatic injury treatment | Engineering | February 18, 2022 | $256,000 |
Questions people ask
How much federal grant money does Nostopharma LLC get?
$2.0 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Nostopharma LLC the most?
The National Science Foundation, with $1.3 million in 2 awards. The Department of Health and Human Services follow.
What is Nostopharma LLC's largest federal grant?
$1.0 million under Technology, Innovation, and Partnerships, with its first action in the period on August 15, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Nostopharma LLC?
Its largest are Technology, Innovation, and Partnerships, National Center for Advancing Translational Sciences and Engineering.
Other grant recipients in Potomac
Largest federal grant recipients in Maryland · Federal grants in Maryland